China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate ...

No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual ...

Asif M, Asif A, Rahman UA, et al. Incidence of glaucoma in type 2 diabetes patients treated with GLP-1 receptor agonists: a systematic review and meta-analysis. 2025;8:e70059. doi:10.1002/edm2 ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a ...

A matched cohort of 139,002 patients was created, with 46,334 patients exposed to GLP-1 RAs and 92,668 unexposed patients.

There are emerging data to suggest patients treated with longer-acting GLP-1 receptor agonists have improved cardiac parameters, some of which are independent of weight and A1c reductions.

A new potential drug treatment for people with type 2 diabetes and obesity lowers blood sugar and increases fat burning.